Actinomycin D Arrests Cell Cycle of Hepatocellular Carcinoma Cell Lines and Induces p53-Dependent Cell Death: A Study of the Molecular Mechanism Involved in the Protective Effect of IRS-4

Actinomycin D Arrests Cell Cycle of Hepatocellular Carcinoma Cell Lines and Induces p53-Dependent Cell Death: A Study of the Molecular Mechanism Involved in the Protective Effect of IRS-4

Actinomycin D (ActD) is an FDA-approved NCI oncology drug that specifically targets and downregulates stem cell transcription factors, which leads to a depletion of stem cells within the tumor bulk. Recently, our research group demonstrated the importance of IRS-4 in the development of liver cancer....

Full description

Bibliographic Details
Main Authors: Luis G. Guijarro, Patricia Sanmartin-Salinas, Eva Pérez-Cuevas, M. Val Toledo-Lobo, Jorge Monserrat, Sofia Zoullas, Miguel A. Sáez, Miguel Angel Álvarez-Mon, Julia Bujan, Fernando Noguerales-Fraguas, Eduardo Arilla-Ferreiro, Melchor Álvarez-Mon, Miguel A. Ortega
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Pharmaceuticals
Subjects:
nuclear IRS-4
PI3K
hepatocellular carcinoma
β-catenin
cyclin D
pH3
Online Access:https://www.mdpi.com/1424-8247/14/9/845

Internet

https://www.mdpi.com/1424-8247/14/9/845

Similar Items